Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 5, 2020 (7 years ago)

Sodium Chloride 0.9% Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviation: Chemical indicators were not positioned properly during sterilization process.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Sodium Chloride 0.9% Injection, USP, 1000 mL bags, Rx only, Manufactured by: Fresenius Medical Care North America, Waltham, MA 02451

Recalling firm
Fresenius Medical Care Holdings, Inc.
Origin
MA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1064-2020 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Fresenius Medical Care Holdings, Inc.

All 2020 recalls
Class II · Moderate risk

Delflex

Lack of Assurance of Sterility: Potential leaks from perforations in bags.

Ongoing Sterility / contamination Fresenius Medical Care Holdings, Inc. D-0513-2026
Class II · Moderate risk

Delflex

Lack of Assurance of Sterility: Potential leaks from perforations in bags.

Ongoing Sterility / contamination Fresenius Medical Care Holdings, Inc. D-0512-2026

Other sterility / contamination recalls from 2020

All sterility / contamination recalls
Class II · Moderate risk

Zerbaxa (ceftolozane and tazobactam)

Lack of assurance of sterility: The results of sterility tests of seven batches of product were out of specification. Five of these batches tested positive for Ralstonia pickettii and two batches produced turbid results that could not be further identified. While all product distributed to the market has met the registered specifications for release, including for sterility, it was manufactured on the same equipment as the affected batches.

Terminated Sterility / contamination Merck Sharp & Dohme NDC 67919-030-01 D-0176-2021